JP7038448B1 - Anti-allergic administration device - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide a technique capable of administering an active ingredient that cannot be used as eye drops to a target. SOLUTION: The administration device (10) according to the present invention is percutaneously or by being brought into contact with the skin around the eyes (31, 32), the skin around the nose (33), or the mucous membrane inside the nostrils. The drug (DR1) can be administered transmucosally, and the antiallergic drug (DR1) contains zinc pyrithione in a content of 5% by weight or less. The administration device (10) has a shape along the first lower edge (31a, 32a) of the eye (31, 32), contains an antiallergic agent (DR1), and mucosa of the lower eyelid (31b, 32b) of the eye. It is preferable to have a first patch member that administers the drug by being attached around the lymphoid tissue. [Selection diagram] Fig. 1

Description

The present invention relates to an administration device and an administration method for transmucosally administering an antiallergic drug.

Conventionally, as a method for alleviating mucosal irritation of the eyes or nose due to allergies such as pollinosis or air pollution, oral medicines or eye drops as anti-inflammatory agents have been used.

Of these, the drug taken had side effects such as lack of immediate effect or accompanied by drowsiness or drowsiness.

In addition, lymphoid tissues or immune cells that cause allergic reactions are concentrated around the eyes (Non-Patent Documents 1 and 2). Therefore, eye drops are also widely used as anti-inflammatory agents. However, with regard to eye drops, the effective action time is short, or it is necessary to frequently instill eye drops on the go, which is complicated. Furthermore, some anti-inflammatory drugs are highly irritating to the eye when instilled in direct contact with the ocular mucosa due to strong acidity, etc., or are difficult to instill due to non-hydrophilicity. Therefore, some of them could not be used as eye drops. Examples of the active ingredient that cannot be used as eye drops include pyrithione ions, pyrithione compounds, pyrithione salts and the like (see Patent Document 1).

Japanese Patent No. 66676779

Knop E, Knop N. The role of eye-associated lymphoid tissue in corneal immune protection. Journal of anatomy. 2005 Mar; 206 (3): 271-85. Brandtzaeg P, Kiyono H, Pabst R, Russell MW. Terminology: nomenclature of mucosa-associated lymphoid tissue. Mucosal immunology. 2008 Jan; 1 (1): 31.

Therefore, it is required to provide a technique capable of administering an active ingredient that cannot be used as eye drops to a target.

The present invention has been made to solve the problems of the prior art as described above, and an effective drug for alleviating or preventing mucosal irritation due to allergies, air pollution, etc. It is an object of the present invention to provide an administration device or an administration method capable of administering a mucosal lymphatic tissue to a target, which is different from the method using the above.

The present inventor has prototyped an antiallergic administration device containing one or more antiallergic agents selected from pyrithione ions, pyrithione salts, and pyrithione compounds as substances having anti-inflammatory or antibacterial activity, and mucosal lymph of the eye. It was found that when applied around the tissue, mucosal irritation symptoms such as tearing, redness, and itching were alleviated. Thereby, the present inventor administers the drug by being brought into contact with the mucosa around the mucosal lymphatic tissue of the eye, around the mucosal lymphatic tissue of the nose, or inside the nostril as a method of alleviating the mucosal irritation caused by pollinosis allergy. Found that the device is valid.

A brief description of the representative inventions disclosed in the present application is as follows.

The administration device as one aspect of the present invention is an administration device that transmucosally administers an antiallergic agent by being brought into contact with the mucosa around the mucosal lymphatic tissue of the eye, around the mucosal lymphatic tissue of the nose, or the mucosa inside the nostril. , The antiallergic agent contains a pyrithion ion, a pyrithion salt, or a pyrithion compound in a content of 5% by weight or less.

Further, the administration method as one embodiment of the present invention is administration in which the drug is administered transmucosally by bringing the antiallergic drug into contact with the mucosa around the mucosal lymphatic tissue of the eye, around the mucosal lymphatic tissue of the nose, or inside the nostril. It is a method, and the antiallergic agent contains a pyrithion ion, a pyrithion salt, or a pyrithion compound in a content of 5% by weight or less.

As described above, lymphoid tissues or immune cells that cause allergic reactions are concentrated around the eyes (Non-Patent Documents 1 and 2). Therefore, as an administration device, an administration device that administers an antiallergic drug transmucosally by being brought into contact with the periphery of the mucosal lymphatic tissue of the eye from around the eye can be considered. As such an administration device for administering a drug from around the eye, for example, a patch-like member fitted to the periphery of the eye, that is, a patch member, or a disposable administration device such as a small poultice can be considered. By attaching such an administration device around the eye, the drug can be efficiently administered to the mucosal lymphatic tissue of the eye.

In addition, as an administration device that administers the drug transmucosally from the mucosa inside the nostril, mucosal irritation is alleviated from the opening of the nostril to the inside of the nostril with a tampon member or a non-woven fabric member having good moisture absorption and breathability. It is conceivable to insert and use an administration device having a drug infiltrated with the drug. By inserting such an administration device into the nostril and bringing it into contact with the mucous membrane inside the nostril, the drug can be efficiently administered transmucosally. It is conceivable to attach a filter to the inner part of the nostril, that is, the part of the inside of the nostril far from the opening. This allows the drug to diffuse from the inspiratory to the back of the nostrils.

By applying one aspect of the present invention, a drug effective for treating an inflammatory disease due to allergy or air pollution, unlike the method using either a swallow or eye drops, is administered to a mucosal lymphatic tissue as a target. Can be done.

It is a figure which shows the administration device of Embodiment 1. FIG. It is a figure which shows the administration device of the 1st modification of Embodiment 1. FIG. It is a figure which shows the administration device of the 2nd modification of Embodiment 1. FIG. It is a figure which shows the administration device of the 3rd modification of Embodiment 1. FIG. It is a figure which shows the tampon member which the administration device of the 3rd modification of Embodiment 1 has. It is a front view which shows the state which the administration device of the 4th modification of Embodiment 1 is attached to the face. It is a figure which shows the tampon member which the administration device of the 4th modification of Embodiment 1 has. It is a side view of the administration device of the 4th modification of Embodiment 1. FIG.

Hereinafter, embodiments of the present invention will be described with reference to the drawings.

It should be noted that the disclosure is merely an example, and those skilled in the art can easily conceive of appropriate changes while maintaining the gist of the invention, which are naturally included in the scope of the present invention. Further, in order to clarify the explanation, the drawings may schematically represent the width, thickness, shape, etc. of each part as compared with the embodiment, but this is just an example, and the interpretation of the present invention is used. It is not limited.

Further, in the present specification and each figure, the same elements as those described above with respect to the above-mentioned figures may be designated by the same reference numerals, and detailed description thereof may be omitted as appropriate.

Further, in the drawings used in the embodiments, hatching (shading) added to distinguish the structures may be omitted depending on the drawings.

In the following embodiments, when the range is indicated as A to B, A or more and B or less are indicated unless otherwise specified.

(Embodiment 1)
<Technical concept of administration device and administration method>
First, the technical concept of the administration device and administration method of Embodiment 1, which is an embodiment of the present invention, will be described. The administration device of the first embodiment is an administration device that administers a drug transmucosally by being brought into contact with the mucosa around the mucosal lymphatic tissue of the eye, around the mucosal lymphatic tissue of the nose, or the mucosa inside the nostril. Further, the administration method of the first embodiment is an administration method in which the drug is administered transmucosally by contacting the drug with the mucosa around the mucosal lymphatic tissue of the eye, around the mucosal lymphatic tissue of the nose, or the mucosa inside the nostril. ..

As described above, conventionally, oral medicines or eye drops as anti-inflammatory agents have been used as a method for alleviating eye or nose irritation caused by pollinosis allergy or air pollution. Of these, the drug taken had side effects such as lack of immediate effect or accompanied by drowsiness or drowsiness. On the other hand, with regard to eye drops, the effective action time is short, or it is necessary to frequently instill eye drops on the go, which is complicated. Furthermore, some anti-inflammatory drugs cannot be used as eye drops because they are highly irritating to the eyes.

The present inventor prototyped a cream containing zincpyrythion as a substance having an anti-inflammatory or antibacterial effect, and applied it around the mucosal lymphatic tissue of the eye to alleviate mucosal irritation symptoms such as lacrimation, redness, and itching. It was found that (Example). Thereby, the present inventor administers the drug by being brought into contact with the mucosa around the mucosal lymphatic tissue of the eye, around the mucosal lymphatic tissue of the nose, or inside the nostril as a method of alleviating the mucosal irritation caused by pollinosis allergy. Found that the device is valid.

Lymphoid tissues or immune cells that cause allergic reactions are concentrated around the eyes (Non-Patent Documents 1 and 2). Therefore, as the administration device, an administration device that administers the drug from around the eyes can be considered. As such an administration device for administering a drug from around the eye, for example, a patch-like member fitted to the periphery of the eye, that is, a patch member, or a disposable administration device such as a small poultice can be considered. By attaching such an administration device around the eye, the drug can be efficiently administered to the mucosal lymphatic tissue of the eye.

Further, it is conceivable to use a non-woven fabric as a material for the patch-shaped member, for example, a transparent member. When such a transparent administration device is used around the eyes, the administration device becomes inconspicuous, so that the administration device can be used without worrying about the appearance.

In addition, as an administration device that administers the drug transmucosally from the mucosa inside the nostril, mucosal irritation is alleviated from the opening of the nostril to the inside of the nostril with a tampon member or a non-woven fabric member having good moisture absorption and breathability. It is conceivable to insert and use an administration device having a drug infiltrated with the drug. By inserting such an administration device into the nostril and bringing it into contact with the mucous membrane inside the nostril, the drug can be efficiently administered transmucosally. It is conceivable to attach a filter to the inner part of the nostril, that is, the part of the inside of the nostril far from the opening. This allows the drug to diffuse from the inspiratory to the back of the nostrils.

Pyrithione ion, pyrithione salt, or a medicinal ingredient other than a pyrithione compound, which is a medicinal ingredient contained in a drug, includes an anti-inflammatory agent, an antihistamine, a vitamin agent, and a drug having an effect on the circulation of capillaries or microvessels. , Antihistamines, antibacterial agents, antibiotics and the like are exemplified. These medicinal ingredients may be an emulsion of water and oil, and an essential oil may be added to the emulsion. This can be expected to improve the drug permeability in addition to the refreshing feeling.

In addition, such administration devices may be useful in eliminating eye or nasal irritation due to other inflammatory diseases, allergies, air pollution different from hay fever. In the present invention and the present embodiment, "allergy" includes various allergic inflammatory diseases different from pollinosis, and includes, for example, allergic conjunctivitis and allergic rhinitis caused by air pollution.

<Administration device and administration method>
Next, the administration device and administration method of Embodiment 1, which is one embodiment of the present invention, will be described. The administration device of the first embodiment is an administration device that administers a drug transmucosally by being brought into contact with the mucosa around the mucosal lymphatic tissue of the eye, around the mucosal lymphatic tissue of the nose, or the mucosa inside the nostril. Further, the administration method of the first embodiment is an administration method in which the drug is administered transmucosally by contacting the drug with the mucosa around the mucosal lymphatic tissue of the eye, around the mucosal lymphatic tissue of the nose, or the mucosa inside the nostril. This is an administration method in which a drug is administered transmucosally using the administration device of the first embodiment.

As a drug administered by the administration device and administration method of the first embodiment, a drug having a medicinal ingredient capable of removing pollinosis or other inflammatory diseases, allergies, or eye or nose irritation due to air pollution is used. It can be used, and a drug containing a pyrithione ion, a pyrithione salt, or a pyrithione compound in a content of 5% by weight or less can be used.

FIG. 1 is a diagram showing an administration device according to the first embodiment. FIG. 1 (a) is a diagram showing a state in which the administration device is attached around the eyes, and FIG. 1 (b) is a front view of the administration device.

As shown in FIGS. 1 (a) and 1 (b), preferably, the administration device 10 of the first embodiment has a patch member 11 and a patch member 12. The patch member 11 has a shape along the lower edge 31a of the right eye 31 as an eye, contains the drug DR1, and is attached to the lower eyelid 31b, which is the lower eyelid of the right eye 31, to administer the drug DR1. do. The patch member 12 has a shape along the lower edge 32a of the left eye 32 as an eye, contains the drug DR1, and is attached to the lower eyelid 32b, which is the lower eyelid of the left eye 32, to administer the drug DR1. do. In addition, in FIG. 1A, the lower eyelid 31b and the lower eyelid 32b are shown by a two-dot chain line (the same applies to FIG. 2A described later).

As a result, the drug DR1 is administered from around the mucosal lymphatic tissue of the eye. Lymphoid tissues or immune cells that cause allergic reactions are concentrated in the lower eyelid 31b and the lower eyelid 32b. Therefore, by attaching the patch member 11 and the patch member 12 to the lower eyelid 31b and the lower eyelid 32b, the drug is administered to the lymphoid tissue or immune cells that gather around the eye and cause an allergic reaction. For example, it is possible to suppress the occurrence of allergic reactions such as pollinosis. Then, a drug effective for alleviating irritation due to allergies, air pollution, etc. can be administered by a method different from the method using either oral medicine or eye drops. Therefore, it has an immediate effect and has less side effects such as drowsiness or drowsiness as compared with a drug taken. In addition, the effective action time can be lengthened as compared with eye drops, and it is not necessary to use it frequently on the go. In addition, a drug containing an anti-inflammatory drug that cannot be used as an eye drop because it is highly irritating to the eyes can also be used as a medicinal ingredient. Examples of such an active ingredient include pyrithione ions, pyrithione compounds, pyrithione salts and the like (Example, Patent Document 1).

As shown in FIGS. 1A and 1B, the patch member 12 is preferably integrally formed with the patch member 11. The patch member integrally formed by the patch member 11 and the patch member 12 is referred to as a patch member 13.

By integrally forming the patch member 11 and the patch member 12 in this way, the number of parts of the administration device 10 is reduced, so that the user can easily attach the administration device 10 and the like. 10 becomes easier to use.

As shown in FIG. 1 (b), the width in the left-right direction when the patch member 13 is used is defined as the width HW1, and the maximum height in the vertical direction when the patch member 13 is used is defined as the height VH1. At this time, the width HW1 can be set to, for example, about 155 mm, and the height VH1 can be set to, for example, about 22 mm. In such a case, the patch member 13 can be attached along the lower edge 31a of the right eye 31 and the lower edge 32a of the left eye 32.

As described above, a transparent patch member can be used as the patch member 11 and the patch member 12. When such a transparent patch member is attached around the eyes, the administration device having the attached patch member becomes inconspicuous, so that the administration device can be used without worrying about the appearance.

<First modification of the administration device>
FIG. 2 is a diagram showing an administration device of the first modification of the first embodiment. FIG. 2A is a diagram showing a state in which the administration device is attached around the mucosal lymphatic tissue of the eye, and FIG. 2B is a front view of the administration device.

The administration device 10 of the first modification can be the same as the administration device of the first embodiment except that the patch member 12 is not integrally formed with the patch member 11.

As shown in FIGS. 2A and 2B, in the first modification, the patch member 12 is separated from the patch member 11. Even in such a case, the drug is administered from around the mucosal lymphatic tissue of the eye. On the other hand, lymphoid tissues or immune cells that cause an allergic reaction are concentrated in the lower eyelid 31b and the lower eyelid 32b. Therefore, when the patch member 11 and the patch member 12 are attached to the lower eyelid 31b and the lower eyelid 32b, the drug is administered to the lymphoid tissue or immune cells that gather around the eye and cause an allergic reaction. Therefore, for example, pollen. It is possible to suppress the occurrence of allergic reactions such as illness. Then, a drug effective for alleviating irritation caused by allergies or air pollution can be efficiently administered to the mucosal lymphatic tissue by a method different from the method using either a swallow or an eye drop.

As shown in FIG. 2B, the length of the patch member 11 along the lower edge 31a of the right eye 31 (see FIG. 2A) and the lower edge 32a of the left eye 32 of the patch member 12 (FIG. 2 (FIG. 2)). Each of the lengths along a)) is defined as the length LN1. At this time, the length LN1 can be set to, for example, about 62 to 67 mm. In such a case, the patch member 11 can be attached along the lower edge 31a of the right eye 31, and the patch member 12 can be attached along the lower edge 32a of the left eye 32.

Note that FIG. 2 illustrates an example in which the patch member 11 and the patch member 12 are attached to each of the right eye 31 and the left eye 32, respectively, but the patch member is attached to only one of the right eye 31 and the left eye 32. May be good.

<Second modification of the administration device>
FIG. 3 is a diagram showing an administration device of the second modification of the first embodiment. FIG. 3A is a diagram showing a state in which the administration device is attached around the nose, and FIG. 3B is a front view of the administration device.

As shown in FIGS. 3A and 3B, the administration device 10 of the second modification has a patch member 14 and a patch member 15. The patch member 14 has a shape along the side edge 34a and the lower edge 34b of the ala of nose 34 on the right side of the nose 33, contains the drug DR1, and is adjacent to the side edge 34a of the ala of nose 34 around the nose 33. The drug DR1 is administered by being attached to the matching portion PR1 and the portion PR2 adjacent to the lower edge 34b of the ala of nose 34. The patch member 15 has a shape along the side edge 35a and the lower edge 35b of the ala of nose 35 on the left side of the nose 33, contains the drug DR1, and has the side edge 35a of the ala of nose 35 around the nose 33. The drug DR1 is administered by being attached to the adjacent portion PR3 and the portion PR4 adjacent to the lower edge 35b of the ala of nose 35.

As a result, the drug DR1 is administered to the mucosal lymphatic tissue at the 33rd site of the nose, which is a portion of the facial skin close to the mucosa inside the nostrils. Therefore, it is possible to suppress the occurrence of allergic reactions such as pollinosis. Then, a drug effective for alleviating mucosal irritation due to allergies or air pollution can be administered by a method different from the method using either oral medicine or eye drops.

The patch member 14 is transmucosally treated by being inserted into the nostril 36, which is a nostril arranged on the same side as the ala of nose 34, and brought into contact with the mucous membrane inside the nostril 36. May be administered. At this time, the patch member 14 has a shape that can be inserted into the nostril 36, contains the drug DR1, and includes a patch member (not shown) attached to the inside of the nostril 36, and the patch member is the main body of the patch member 14. It is formed integrally with. Further, the patch member 15 is transmucosally treated by being inserted into the nostril 37, which is a nostril arranged on the same side as the ala of nose 35 among the two nostrils, and brought into contact with the mucous membrane inside the nostril 37. May be administered. At this time, the patch member 15 has a shape that can be inserted into the nostril 37, contains the drug DR1, and includes a patch member (not shown) attached to the inside of the nostril 37, and the patch member is the main body of the patch member 15. It is formed integrally with. This makes it possible to more efficiently suppress the occurrence of allergic reactions such as pollinosis.

Further, FIGS. 3A and 3B exemplify an example in which the patch member 14 and the patch member 15 are attached to the side edges and lower edges of the nasal wing portions 34 and the nasal wing portions 35 on both the left and right sides, respectively. However, the patch member 14 or the patch member 15 may be attached only to the side edge and the lower edge of any one of the two nose wing portions 34 and the nose wing portion 35 on the left and right sides. Even in such a case, the administration device 10 can efficiently administer the drug DR1 to the mucosal lymphatic tissue of the nose 33.

Further, the patch member of the second modification and the patch member of the first modification of the first embodiment or the first embodiment may be used in combination. As a result, the effect obtained when the patch member of the second modification is used and the effect obtained when the patch member of the first modification of the first embodiment or the first embodiment are used are added together. The effect is obtained.

<Third variant of the administration device>
FIG. 4 is a diagram showing an administration device of the third modification of the first embodiment. FIG. 4 (a) is a front view of the administration device inserted inside the nostril, and FIG. 4 (b) shows the nose and the administration device downward with the administration device inserted inside the nostril. It is a figure seen from. FIG. 5 is a diagram showing a tampon member included in the administration device of the third modification of the first embodiment. 5 (a) is a front view of the tampon member, and FIG. 5 (b) is a side view of the tampon member.

The administration device of the third modification is different from the administration device of the first embodiment in that it has a tampon member.

As shown in FIGS. 4 and 5, the administration device 10 of the third modification has a tampon member 16 and a tampon member 17. The tampon member 16 has a shape that can be inserted into the nostril 36, which is a nostril arranged on the same side as the ala of nose 34 among the two nostrils, contains the drug DR1, and is inserted into the nostril 36. The drug is administered transmucosally by being brought into contact with the mucosa inside the nostril. The tampon member 17 has a shape that can be inserted into the nostril 37, which is a nostril arranged on the same side as the ala of nose 35 among the two nostrils, contains the drug DR1, and is inserted into the nostril 37. The drug DR1 is administered transmucosally by being brought into contact with the mucosa inside the nostril.

As a result, the drug DR1 is efficiently administered transmucosally from the mucous membrane inside the nostril. Therefore, it is possible to efficiently suppress the occurrence of allergic reactions such as pollinosis. Then, a drug effective for alleviating mucosal irritation due to allergies or air pollution can be administered by a transmucosal method, which is a method different from the method using either oral medicine or eye drops.

As shown in FIGS. 5A and 5B, the height of the tampon member 16 and the tampon member 17 in the vertical direction at the time of use is defined as the height VH2, and each of the tampon member 16 and the tampon member 17 is set to height VH2. The thickness in the depth direction when viewed from the front during use is defined as the thickness TH1. Further, the width in the left-right direction of the upper end portion when each of the tampon member 16 and the tampon member 17 is used is the width HW2, and the width in the left-right direction of the lower end portion when each of the tampon member 16 and the tampon member 17 is used is the width HW3. And.

At this time, the height VH2 can be set to, for example, about 15 mm, the thickness TH1 can be set to, for example, about 3 to 5 mm, the width HW2 can be set to, for example, about 5 mm, and the width HW3 can be set to about 5 mm. For example, it can be about 7 to 10 mm. That is, each of the tampon member 16 and the tampon member 17 when viewed from the front when each of the tampon member 16 and the tampon member 17 is used can have a trapezoidal shape.

In such a case, the tampon member 16 can be easily inserted into the nostril 36 at the start of use, and the tampon member 16 can be easily held in contact with the mucous membrane inside the nostril 36 during use. The tampon member 16 can be easily pulled out from the nostril 36 at the end of use. Further, at the start of use, the tampon member 17 can be easily inserted into the nostril 37, and during use, the tampon member 17 can be easily held in contact with the mucous membrane inside the nostril 37. At the end of use, the tampon member 17 can be easily pulled out from the nostril 37.

Note that FIG. 4 illustrates an example in which the tampon member 16 and the tampon member 17 are inserted into the nostrils 36 and the nostrils 37 on the left and right sides, respectively, but one of the nostrils 36 and the nostrils 37 on the left and right sides is illustrated. The tampon member 16 or the tampon member 17 may be inserted only inside the tampon member 16. Even in such a case, since the administration device can come into contact with a part of the mucous membrane inside one of the two nostrils, the drug DR1 can be efficiently administered transmucosally.

Further, the tampon member of the third modification and the patch member of the first modification of the first embodiment or the first embodiment may be used in combination. As a result, the effect obtained when the tampon member of the third modification is used and the effect obtained when the patch member of the first modification of the first embodiment or the first embodiment is used are added together. The effect is obtained.

<Fourth variant of the administration device>
FIG. 6 is a front view showing a state in which the administration device of the fourth modification of the first embodiment is attached to the face. FIG. 7 is a diagram showing a tampon member included in the administration device of the fourth modification of the first embodiment. 7 (a) is a front view of the tampon member, and FIG. 7 (b) is a side view of the tampon member. FIG. 8 is a side view of the administration device of the fourth modification of the first embodiment. In FIG. 6, the mask portion 18 is shown by a two-dot chain line.

The administration device of the fourth modification is different from the administration device of the third modification of the first embodiment in that it has a mask portion and two locking portions.

As shown in FIGS. 6 to 8, the administration device 10 of the fourth modification has the tampon member 16 and the tampon member 17 as in the administration device 10 of the third modification of the first embodiment. As a result, the drug DR1 is efficiently administered transmucosally from the mucous membrane inside the nostril. Therefore, it is possible to efficiently suppress the occurrence of allergic reactions such as pollinosis. Then, a drug effective for alleviating mucosal irritation due to allergies or air pollution can be administered by a transmucosal method, which is a method different from the method using either oral medicine or eye drops.

Further, as shown in FIGS. 7 (a) and 7 (b), in the fourth modified example as well, the height VH2 may be set to, for example, about 15 mm as in the third modified example of the first embodiment. The thickness TH1 can be, for example, about 3 to 5 mm, the width HW2 can be, for example, about 5 mm, and the width HW3 can be, for example, about 7 to 10 mm.

In such a case, the tampon member 16 can be easily inserted into the nostril 36 at the start of use, and the tampon member 16 can be easily held in contact with the mucous membrane inside the nostril 36 during use. The tampon member 16 can be easily pulled out from the nostril 36 at the end of use. Further, the tampon member 17 can be the same as the tampon member 16.

On the other hand, as shown in FIGS. 6 to 8, the administration device 10 of the fourth modification is different from the administration device 10 of the third modification of the first embodiment, and has a mask portion 18 and two locking portions 19. And have. The mask portion 18 is made of, for example, a non-woven fabric and covers the nose tip 38 and the mouth 39 of the nose 33 in the face. The two locking portions 19 are provided on the left side portion and the right side portion of the mask portion 18, respectively, and are each made of, for example, a rubber cord, and the mask portion 18 is locked to each of the right ear 40 and the left ear 41, respectively. do. Further, both the tampon member 16 and the tampon member 17 are attached to the inner surface of the mask portion 18. Both the tampon member 16 and the tampon member 17 are connected to the inner surface of the mask portion 18 via a movable connecting portion 20 made of, for example, a stretchable rubber thread, or an adhesive tape (not shown) is attached. It is pasted through.

In this way, the tampon member 16 and the tampon member 17 are attached to the inner surface of the mask portion 18, and the mask portion 18 to which the tampon member 16 and the tampon member 17 are attached to the inner surface is attached to the face by the locking portion 19. The tampon member 16 and the tampon member 17 can be easily brought into contact with the mucous membrane inside the nostril.

Note that FIG. 6 illustrates an example in which the tampon member 16 and the tampon member 17 are inserted into the nostrils 36 and the nostrils 37 on the left and right sides, respectively, but one of the nostrils 36 and the nostrils 37 on the left and right sides is illustrated. The tampon member 16 or the tampon member 17 may be inserted only inside the tampon member 16. Even in such a case, since the administration device 10 can come into contact with a part of the mucous membrane inside one of the two nostrils, the drug DR1 can be efficiently administered transmucosally.

Further, the tampon member of the fourth modification and the patch member of any one of the first modification of the first embodiment and the first modification of the first embodiment may be used in combination. As a result, the effect obtained when the tampon member of the fourth modification is used and the effect obtained when the patch member of the first modification of the first embodiment or the first embodiment is used are added together. The effect is obtained.

<Drugs administered by administration device and administration method>
Next, a drug to be administered according to the administration device and administration method of the first embodiment will be described. The same can be applied to the drug administered by the administration device of the first modification to the fourth modification of the first embodiment.

As described above, as the drug administered by the administration device and administration method of the first embodiment, a medicinal effect capable of removing pollinosis and other inflammatory diseases, allergies, or eye or nose irritation due to air pollution. A drug having an ingredient can be used.

The drug administered by the administration device and administration method of the first embodiment preferably contains, for example, the following medicinal properties.

The drug of the first embodiment may be instilled because of its medicinal properties, non-hydrophilicity, etc., which may cause eye irritation when instilled and in direct contact with the ocular mucosa due to strong acidity or the like. It is preferable to contain a difficult medicinal ingredient or a medicinal ingredient that can obtain a longer action time than when instilled.

Examples of such medicinal ingredients include pyrithione ions, pyrithione salts, or pyrithione compounds. As the drug, it is preferable to use a drug containing a pyrithione ion, a pyrithione salt, or a pyrithione compound in a content of 5% by weight or less. Further, as the drug, it is more preferable to use a drug containing a pyrithione ion, a pyrithione salt, or a pyrithione compound in a content of 2.5% by weight or less, and 1.0% by weight of a pyrithione ion, a pyrithione salt, or a pyrithione compound. It is even more preferable to use a drug containing the following content, and most preferably a drug containing a pyrithione ion, a pyrithione salt, or a pyrithione compound in a content of 0.1% by weight or less (Example).

In the specification of the present application, the content of pyrithione ion, pyrithione salt, or pyrithione compound in the drug is the weight ratio of the pyrithione compound to the total weight of the liquid component including the water-soluble fraction and the fat-soluble fraction. Means (the same applies to the following contents).

Alternatively, the pH of the agent is preferably adjusted using a pharmacologically acceptable pH regulator. That is, the drug preferably contains a pH adjuster. As the pH adjusting agent, for example, a pH adjusting agent containing phosphoric acid, citric acid, acetic acid, glycine and the like can be used. The pH of the agent adjusted with the pH adjuster is preferably 4.0 to 7.0, more preferably 4.5 to 6.5. By setting the pH in such a range, the medicinal effect can be maximized (Patent Document 1). Further, the concentration of the pH adjuster is preferably 1 to 100 mM, more preferably 10 to 50 mM. Such acidic pyrithione causes pain in the eyes when instilled, and has strong side effects when systemically administered by swallowing drugs, so that there is a problem that it cannot be used by the administration method such as eye drops or swallowing drugs. It can be administered by an administration device or an administration method.

In addition to pyrithione ions, pyrithione salts, or pyrithione compounds, drugs whose effective concentration cannot be maintained due to systemic administration by swallowing or injection, drugs whose effective concentration cannot be used due to side effects on the whole body, eye drops, etc. Drugs that cannot be used by the method due to pain, tingling sensation, and side effects on the eyes can also be administered by the administration device or administration method as one embodiment of the present invention.

Alternatively, the drug preferably contains a water-soluble metal salt in a content of 1% by weight or less. Such a water-soluble metal salt is, for example, a water-soluble zinc salt typified by zinc sulfate, for example, a water-soluble copper salt typified by copper sulfate, a water-soluble iron salt, or a metal other than zinc, copper and iron. Contains water-soluble metal salts of. It is expected that the anti-inflammatory action of the pyrithione compound will be enhanced by containing the water-soluble metal salt (Patent Document 1).

Alternatively, the drug preferably contains vitamin C or a vitamin C derivative in a content of 10% by weight or less, and more preferably in a content of 1% by weight or less. It is expected that the anti-inflammatory effect of the pyrithione compound will be enhanced by setting the content in such a range (Patent Document 1).

Alternatively, the drug may contain at least one selected from the B vitamin group or at least one derivative selected from the B vitamin group in a content of 10% by weight or less, and a content of 1% by weight or less. It is more preferable to contain it in an amount. It is expected that the anti-inflammatory effect of the pyrithione compound will be enhanced by setting the content in such a range (Patent Document 1).

Alternatively, the drug may contain bisabolol in a content of 5% by weight or less, more preferably 1% by weight or less.

Alternatively, the drug may contain hinokitiol in a content of 5% by weight or less, more preferably 1% by weight or less.

Alternatively, the drug may contain salicylic acid or salicylic acid salt in a content of 10% by weight or less, more preferably 1% by weight or less.

Alternatively, the drug may contain curcumin or a curcumin derivative in a content of 10% by weight or less, more preferably 1% by weight or less.

Alternatively, the agent may contain a grape seed extract, a tea leaf extract, or a marine plankton extract in a content of 10% by weight or less, more preferably 1% by weight or less. ..

Alternatively, the agent may contain an amino acid or an amino acid derivative (eg, a leucine derivative (beta-Hydroxy-beta-methyl-butyrate (HMB))) in a content of 10% by weight or less, or 1% by weight or less. It is more preferable to contain it in terms of content.

Alternatively, the drug may contain N-acetylcysteine or an N-acetylcysteine derivative in a content of 10% by weight or less, more preferably 1% by weight or less.

Alternatively, the drug may contain glutathione or a glutathione derivative in a content of 10% by weight or less, more preferably 1% by weight or less.

Alternatively, the drug may contain gamma-glutamylcysteine or a gamma-glutamylcysteine derivative in a content of 10% by weight or less, more preferably 1% by weight or less.

Alternatively, the agent may be an allantin or an allantin derivative, a resveratrol or a resveratrol derivative, luteolin or a luteolin derivative, velverine or a velverin derivative, or a catechin group compound or a catechin group compound derivative, an antipruritic agent, or an antihistamine. It may be contained in a content of 1% by weight or less, and more preferably 1% by weight or less.

Alternatively, the drug may contain an antibiotic or a steroid in a content of 10% by weight or less, more preferably in a content of 1% by weight or less.

Alternatively, the agent may contain a fat-soluble component and a water-soluble component.

The drug may contain a fatty acid or a fatty acid derivative as a fat-soluble component, and in particular, an omega-3 unsaturated fatty acid such as docosahexaenoic acid and eicosapentaenoic acid, and its derivative, oleic acid and other unsaturated fatty acids. Selected from the group consisting of fatty acids and their derivatives, lipid cholesterol and its derivatives which are constituents of biological membranes, sphingolipids and their derivatives, glycolipids and their derivatives, phospholipids and their derivatives and metabolites, and their structurally similar substances. At least one may be contained. Further, the drug may contain a fat-soluble active ingredient, a shape-retaining agent, an emulsifier, a stabilizer, an adjusting agent or a permeability enhancer as the fat-soluble component.

The drug may contain water as a main component as a water-soluble component, and as a water-soluble component, a water-soluble active ingredient, a pH adjuster, some emulsifiers, a shape-retaining agent, a stabilizer, a preservative or a permeability. It may contain an enhancer.

Further, an ointment, lotion, solution, gel or emulsion may be formed by a fat-soluble component, a water-soluble component and an emulsifier.

In addition, the agent may contain a surfactant, a permeability enhancer, a stabilizer, a shape retaining agent, an emulsifier, a preservative, an adjusting agent or a skin protective agent.

Alternatively, the permeability enhancer may contain terpenes, terpenoids, azones, pyrrolidones or menthol. Alternatively, the permeability enhancer may contain an essential oil typified by a tea extract, a tea essential oil, a mint oil or the like. Alternatively, the permeability enhancer may contain a dextrin compound or a dextrin derivative, polyethylene glycol, or a synthetic peptide.

Dextrin derivatives, peptides, medicinal ingredients and pH regulators can all be dissolved in water-soluble or fat-soluble components depending on the chemical shape of these substances when preparing liquid components having shapes such as creams and lotions. .. Most peptides are water-soluble, but some are fat-soluble. Dextrin dissolves in both water and oil, but can be dissolved in fat-soluble components. Since the pH adjuster is water-soluble, the pH can be adjusted by mixing it with other water-soluble components. When the water-soluble component and the fat-soluble component are dissolved, the water-soluble component and the fat-soluble component may be mixed to form an emulsion, cream, lotion, etc. in the presence of an emulsifier, a surfactant, or a solid agent. can.

The shape-retaining agent, stabilizer, emulsifier, preservative and excipient are all mixed with the water-soluble fraction when they are water-soluble, and mixed with the fat-soluble fraction when they are fat-soluble. Most shape-retaining agents are fat-soluble, stabilizers are water-soluble or fat-soluble, and many emulsifiers are fat-soluble, but there are also water-soluble emulsifiers. Many preservatives are water soluble. The modifier is water-soluble or fat-soluble. However, for substances that are inactivated at high temperatures, such as some stabilizers and preservatives, or many medicinal ingredients, the temperature is determined after the water-soluble fraction and the fat-soluble fraction are mixed to form an emulsion. It is desirable to add it after it has dropped.

Transmucosal administration of the drug is to contact creams, ointments, lotions, gels, solid sticks, sprays or drops (eye drops, nasal drops and the like) with pharmaceutically acceptable salts. It may be done by. The liquid component of the drug may be an oil-in-water emulsion, a water-in-oil emulsion, a viscous liquid or a water-soluble solution. In addition, a dosing device such as a semi-permeable membrane covering a reservoir containing the pyrithione compound and other active ingredients may be used to release the pyrithione compound and other active ingredients such as steroids and anti-inflammatory agents. .. Ingredients contained in the agent for administering the pyrithione compound include, for example, emulsifiers, surfactants, stabilizers, thickeners, moisturizers, skin conditioning agents, skin protectants and sunscreens. Preservatives and bacteriostatic agents such as methyl hydroxybenzoate, propyl hydroxybenzoate and chlorocresol may be contained in the agent.

Further, in order to enhance the absorption efficacy of the active ingredient, the drug may contain a chemical substance penetration enhancer and a solubilization accelerator. The chemical penetration enhancer may include unsaturated fatty acids such as oleic acid, docosahexaenoic acid or eicosapentaenoic acid, peptides, terpenes, terpenoids, essential oils, azones, or pyrrolidones. The solubilization accelerator may contain a surfactant, cyclodextrin or dimethyl sulfoxide (DMSO).

(Embodiment 2)
In the first embodiment, a method of administering a drug using an administration device having a patch member or a tampon member has been described. On the other hand, the drug may be administered transmucosally without using the administration device, for example, by applying or spraying the drug. The administration method by applying or spraying such a drug will be described as the administration method of Embodiment 2. The administration method of the second embodiment is also the same as the administration method of the first embodiment, by contacting the drug with the mucosa around the mucosal lymphatic tissue of the eye, around the mucosal lymphatic tissue of the nose, or the mucosa inside the nostril. It is a kind of administration method in which a drug is administered mucosally.

The drug administered by the administration method of the second embodiment is the same as the administration device and the drug administered by the administration method of the first embodiment, and at least 5 weights of a pyrithione ion, a pyrithione salt, or a pyrithione compound is added. It is contained in a content of% or less, and detailed description thereof will be omitted.

As an example of the administration method of the second embodiment, there is an administration method in which the drug is administered around the mucosal lymphatic tissue of the eye or around the mucosal lymphatic tissue of the nose. Specifically, the drug can be administered by applying a cream, an ointment, a lotion, a gel, a solid stick, a spray, or the like, as in the case of some of the various administration methods described in the first embodiment. Further, as in the first embodiment, the drug may contain water as a main component as a water-soluble component, and may contain an ointment, lotion, solution, gel or emulsion depending on the fat-soluble component, the water-soluble component and the emulsifier. May be formed.

<Modified Example of Embodiment 2>
In the second embodiment, an administration method in which the drug is administered by applying the drug around the mucosal lymphatic tissue of the eye or around the mucosal lymphatic tissue of the nose has been described. On the other hand, the drug may be administered transmucosally, for example, by spraying the drug. The administration method by spraying the drug in this way will be described as the administration method of the modified example of the second embodiment. The administration method of this variant is also transmucosal by contacting the drug with the mucosa around the mucosal lymphatic tissue of the eye, around the mucosal lymphatic tissue of the nose, or inside the nostril, as in the administration method of Embodiment 1. It is a kind of administration method for administering a drug to the nose.

The drug administered by the administration method of this variant is the same as that of the administration device and administration method of Embodiment 1, and at least 5% by weight or less of pyrithione ion, pyrithione salt, or pyrithione compound. It is contained in the content of, and detailed description thereof will be omitted.

As an example of the administration method of this modified example, there is an administration method in which a drug is sprayed into the nostril and the sprayed drug is brought into contact with the mucous membrane inside the nostril to administer the drug transmucosally. Specifically, as in the case of some of the various administration methods described in the first embodiment, the drug is transmucosally administered by spraying a spray or a drop (eye drops, nasal drops and the like). Can be administered. Further, as in the first embodiment, the drug may contain water as a main component as a water-soluble component, and may contain an ointment, lotion, solution, gel or emulsion depending on the fat-soluble component, the water-soluble component and the emulsifier. May be formed.

Although the invention made by the present inventor has been specifically described above based on the embodiment thereof, the present invention is not limited to the embodiment and can be variously modified without departing from the gist thereof. Needless to say.

In the scope of the idea of the present invention, those skilled in the art can come up with various modified examples and modified examples, and it is understood that these modified examples and modified examples also belong to the scope of the present invention.

For example, a person skilled in the art appropriately adds, deletes, or changes the design of each of the above-described embodiments, or adds, omits, or changes the conditions of the process of the present invention. As long as it has a gist, it is included in the scope of the present invention.

<Example> Effect of cream containing active ingredient such as zinc pyrithione [Experimental method]
Regarding whether it is possible to improve the symptoms of volunteer subjects who have inflammation and allergic symptoms on the mucous membranes of the nose and eyes by supplying a cream containing an active ingredient such as zinc pyrithione to the area around the eyes and the nasal cavity. Verification was performed. The composition of the cream is as follows.

[ Ingredient composition of zinc pyrithione-containing cream]
Zinc pyrithione: 0.1% by weight
Pyridoxine dicaprylate: 0.2% by weight
Glycerol: 5% by weight
Polysorbate 20: 1% by weight
1 molar solution of citric acid: 0.7% by weight
1 molar solution of sodium citrate: 1.3% by weight
Behenyl alcohol: 3% by weight
Cetanol: 3% by weight
Glyceryl stearate: 1% by weight
Stearic acid: 1% by weight
Sorbitan stearate: 1% by weight
Cetyl palmitate: 0.5% by weight
Dimethicone: 1% by weight
Tea tree oil: 0.03% by weight
Distilled water: the amount required to make the total volume 100%

[Ingredient composition of cream without zinc pyrithione]
Glycerol: 5% by weight
Polysorbate 20: 1% by weight
1 molar solution of citric acid: 0.7% by weight
1 molar solution of sodium citrate: 1.3% by weight
Behenyl alcohol: 3% by weight
Cetanol: 3% by weight
Glyceryl stearate: 1% by weight
Stearic acid: 1% by weight
Sorbitan stearate: 1% by weight
Cetyl palmitate: 0.5% by weight
Dimethicone: 1% by weight
Tea tree oil: 0.03% by weight
Distilled water: the amount required to make the total volume 100%

First, subjects were randomly assigned to two groups. Subjects were not informed about the ingredients of the two creams. The first group used a zinc pyrithione-containing cream on the first day, and two days apart, a zinc pyrithione-free cream was used on the fourth day, whereas the second group used the zinc pyrithione-free cream on the first day. A crossover comparative study was conducted in which a cream containing zinc pyrithione was used and a cream containing zinc pyrithione was used on the fourth day at intervals of 2 days. Questionnaire form for subjects on the day of the test on the first and fourth days, before using the cream, after 30 minutes, after 2 hours, after 6 hours, before sleeping on the day of the test, and when waking up the next morning. I had you describe it in.

The content of the questionnaire is a four-level numerical display (0: no symptoms; 1: Mild; 2: Moderate; 3: Severe), and a description of whether or not there was a side effect and, if so, its severity. Further statements were added as appropriate if the subject so wished. The total score of the severity of symptoms at each time point is defined as the severity score at that time point.

Tables 1A and 1B show mucosal irritation symptoms such as the nose and eyes when the zinc pyrithione-containing cream is applied to the lower eyelids and around the nasal cavity and when the zinc pyrithione-free cream is applied to subjects with mucosal irritation symptoms such as the nose and eyes. It is a table summarizing the effects on.

[Results and discussion]
Subject 1: The severity score of the zinc pyrithione-containing cream on the first day was 10 points before the start of the test, but 30 minutes after the use of the pyrithione-containing cream, a decrease of 5 points was already observed. It was effective against both nasal and eye symptoms, and this symptom-relieving effect lasted up to 6 hours after the use of the cream. On the other hand, the severity score before the start of the test with the zinc pyrithione-free cream on the 4th day was 4 points, and although there was 1 point of symptom relief 6 hours after the use of the cream, further symptom changes were observed. I didn't.

Subject 2: The severity score of the zinc pyrithione-containing cream on the first day was 12 points before the start of the test, but symptoms gradually improved from 30 minutes after the start of the use of the zinc pyrithione-containing cream, and the severity was severe before sleep on the day of the test. The score improved to 6 points, and this symptom improvement effect continued until the next morning when waking up. In contrast, the severity score, which was 12 points before the use of the zinc pyrithione-free cream on the 4th day, only decreased to 10 points after 6 hours of cream application.

Subject 3: The severity score, which was 9 points before the start of the test with the zinc pyrithione-free cream on the first day, was 6 points 30 minutes after the use of the zinc pyrithione-free cream and up to 3 points 2 hours later. After the decrease, it increased again and deteriorated to almost the original state before sleep on the day. On the other hand, on the 4th day, the severity score, which was 9 points before the use of the zinc pyrithione-containing cream, has already decreased to 3 points 30 minutes after the use of the zinc pyrithione-containing cream, and once increased to 5 points after 2 hours, but 6 hours. Later, it dropped to 1 point again, at which point all symptoms except nasal congestion disappeared completely.

Subject 4: The severity score, which was 6 points before the start of the zinc pyrithione-free cream test conducted on the first day, gradually decreased after the use of the zinc pyrithione-free cream and decreased to 2 points after 6 hours. .. However, the questionnaire on the first day of this subject contained a comment from the subject that did not reflect the trend of the severity score that "the effect of this cream (cream without zinc pyrithione) is not so clear". In contrast, the severity score, which was 4 points before the start of the test with zinc pyrithione-containing cream on the 4th day, was 2 points 30 minutes after application of the zinc pyrithione-containing cream, 1 point 2 hours later, and finally 6 hours later. Improve to 0 points.

Subject 5 (missing number): In addition to the above 4 cases, one more case, after using a cream containing zinc pyrithione on the first day of the test, complained of irritation and discomfort in the eyes, so the test was immediately discontinued. This result is not included in this table.

From the above, it is suggested that the application of zinc pyrithione around the lower eyelid and the nasal cavity once a day has a relieving effect on the symptoms of mucosal irritation of the nose and eyes. If the severity score before the start of the test was less than 10, the cream without zinc pyrithione tended to have a slight symptom improvement effect, but the cream with zinc pyrithione was more symptomatic. The improvement effect was high. Subjects with a severity score of 10 or higher and subjects with a severity score of less than 10 may have different pathologies, and zinc pyrithione may act more effectively on pathologies with a severity score of 10 or higher.

10 Administration device 11 to 15 Patch member 16, 17 Tampon member 18 Mask part 19 Locking part 20 Movable connecting part 31 Right eye 31a, 32a Lower edge 31b, 32b Lower eyelid 32 Left eye 33 Nose 34, 35 Nostril part 34a, 35a side Edge 34b, 35b Lower edge 36, 37 Nostril 38 Nostril 39 Mouth 40 Right ear 41 Left ear DR1 Drug HW1 to HW3 Width LN1 Length PR1 to PR4 Part TH1 Thickness VH1, VH2 Height

Claims (19)

In an administration device for transmucosally administering an antiallergic agent from around the mucosal lymphatic tissue of the eye, the antiallergic agent contains a pyrithione ion, a pyrithione salt, or a pyrithione compound in a content of 5% by weight or less. Dosing device for anti-allergy. In the administration device according to claim 1,
It has a shape along the first lower edge of the eye, contains the antiallergic agent, and has a first patch member for administering the antiallergic agent by being attached around the mucosal lymphoid tissue of the lower eyelid of the eye. , Dosing device. In the administration device according to claim 2,
The antiallergic agent is administered by being attached to the first lower eyelid having a shape along the second lower edge of the left eye, containing the antiallergic agent, and having the mucosal lymphoid tissue of the lower eyelid of the left eye. Has 2 patch members
The first patch member has a shape along the first lower edge of the right eye as the eye, and is attached to the second lower eyelid where the mucosal lymphoid tissue of the lower eyelid of the right eye is located, thereby causing the antiallergic reaction. A dosing device that administers a drug. In the administration device according to claim 3,
The second patch member is an administration device integrally formed with the first patch member. In a dosing device that transmucosally administers an antiallergic drug from around the nasal mucosal lymphoid tissue and from inside the nostrils.
It has a shape along the lateral and inferior edges of the right or left ala of nose, contains the antiallergic agent, is adjacent to the lateral edge of the ala of nose, and is below the ala of nose. It has a patch member A that administers the antiallergic agent by being attached to a portion adjacent to the edge.
The antiallergic agent is an antiallergic administration device containing a pyrithione ion, a pyrithione salt, or a pyrithione compound in a content of 5% by weight or less . In the administration device according to claim 5,
Of the two nostrils, it has a shape that can be inserted into the first nostril, which is a nostril arranged on the same side as the ala of nose, contains the antiallergic agent, and is mounted inside the first nostril. It has a patch member B that transmucosally administers the antiallergic agent by being brought into contact with the mucous membrane inside the first nostril.
The patch member B is an administration device integrally formed with the patch member A. In a dosing device that transmucosally administers an antiallergic drug from around the nasal mucosal lymphoid tissue and from inside the nostrils.
A tampon member having a shape that can be inserted into the nostril, containing the antiallergic agent, and transmucosally administering the antiallergic agent by being inserted into the nostril and brought into contact with the mucous membrane inside the nostril. Have,
The antiallergic agent contains a pyrithione ion, a pyrithione salt, or a pyrithione compound in a content of 5% by weight or less.
Administration device for anti-allergy . In the administration device according to claim 7,
Of the face, the tip of the nose and the mask part that covers the mouth,
Two locking portions provided on each of the left side portion and the right side portion of the mask portion and locking the mask portion to each of the right ear and the left ear, respectively.
Have,
The administration device in which the tampon member is connected to the inner surface of the mask portion via a movable connecting portion or is attached by an adhesive tape. The administration device according to any one of claims 1 to 8.
The antiallergic drug is
It contains a pH adjuster that adjusts the pH of the antiallergic agent.
The concentration of the pH adjuster is 1 to 100 mM.
The administration device, wherein the pH of the antiallergic agent is 4.0-7.0. In the administration device according to claim 9,
The pH regulator is a dosing device comprising phosphoric acid, citric acid, acetic acid or glycine. In the administration device according to any one of claims 1 to 10.
The antiallergic agent is an administration device containing a water-soluble metal salt in a content of 1% by weight or less. In the administration device according to claim 11,
The administration device, wherein the water-soluble metal salt comprises a water-soluble zinc salt, a water-soluble copper salt or a water-soluble iron salt. The administration device according to any one of claims 1 to 12.
The administration device, wherein the antiallergic agent contains at least one selected from the vitamin C or vitamin B group in a content of 10% by weight or less. In the administration device according to any one of claims 1 to 13.
The antiallergic agent is an administration device containing bisabolol or hinokitiol in a content of 5% by weight or less. The administration device according to any one of claims 1 to 14.
The antihistamines include salicylic acid, salicylate, curcumin, grape seed extract, tea leaf extract, marine plankton extract, amino acids , N - acetylcysteine, glutathione, gamma -glutamylcysteine , allantin , and resvera. A dosing device comprising tralol , luteolin , velverine , a catechin group compound , an antipruritic agent, or an antihistamine in a content of 10% by weight or less. The administration device according to any one of claims 1 to 15.
The antiallergic agent is an administration device containing an antibiotic or a steroid in a content of 10% by weight or less. The administration device according to any one of claims 1 to 8.
The antiallergic drug is
The first component, which is a fat-soluble component, and
The second component, which is a water-soluble component, and
Contains,
The first component contains a fatty acid and contains
The second component comprises a first emulsifier, a first shape-retaining agent, a first stabilizer, a first preservative or a first permeability enhancer.
An administration device in which an ointment, lotion, solution, gel or emulsion is formed by the first component and the second component. In the administration device according to claim 17,
The antiallergic agent is a dosing device containing a surfactant, a second permeability enhancer, a second stabilizer, a second shape-retaining agent, a second emulsifier, a second preservative, a modifier or a protective agent. In the administration device of claim 18,
The administration device comprising the second permeability enhancer terpenes, terpenoids, azones, pyrrolidones, menthol, essential oils, dextrin compounds , polyethylene glycols, or synthetic peptides.

Images